Zhuang Tian

Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis

Yang Lu, Yuanyuan Zhu, Zhuang Tian

Background: Recent advancements have introduced novel cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in treating hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to clarify the current understanding of the impact of CMIs on echocardiographic cardiac structure and function in patients with …

cn (code pays fourni par la source)

Association of Rare Variants in Pulmonary Arterial Hypertension-Related Genes With a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients With Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension

Junyan Qian, Xinzhuang Yang, Qian Wang, Jiuliang Zhao et autres

cn (code pays fourni par la source)

Genetic landscape of hereditary cardiomyopathies and arrhythmias in China

Lu Yang, Zeyuan Wang, Shuyuan Zhang, Yaping Liu et autres

cn (code pays fourni par la source)

Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy

Zhuang Tian, Liwen Li, Xiaoyan Li, Qing Zhang et autres

BACKGROUND: Mavacamten, a first-in-class cardiac myosin inhibitor and the only approved cardiac myosin inhibitor worldwide, improved clinical symptoms and health status in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in phase 3 EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With …

cn, hk (code pays fourni par la source)

Hereditary transthyretin cardiac amyloidosis with Glu109Lys mutation presenting with low sensitivity to 99mTc pyrophosphate in scintigraphy: a case description

Yun-Peng Wei, Dachun Zhao, Xiao Li, Chao Ren et autres

cn (code pays fourni par la source)

Correction: Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care

Julian D. Gillmore, Katrin Hahn, J. G. Smith, Isabel Conceição et autres

gb, de, se, pt, cn, us, ca (code pays fourni par la source)

Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy

Zhuang Tian, Daoquan Peng, Wei Ma, Jiangtao Yan et autres

INTRODUCTION: Tafamidis is approved in many countries for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Approval is largely based on findings from an international phase 3 trial. This post-approval commitment study aimed to evaluate the safety and efficacy of tafamidis …

cn (code pays fourni par la source)

Effect of Mavacamten on Echocardiographic Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the EXPLORER-CN Study

Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang et autres

Mavacamten, a cardiac myosin inhibitor, has demonstrated positive outcomes in left ventricular outflow tract (LVOT) gradient reduction and improvements of symptoms and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in EXPLORER-CN. This exploratory analysis aimed to evaluate the effect …

cn, hk, us (code pays fourni par la source)

Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care

Julian D. Gillmore, Katrin Hahn, J. G. Smith, Isabel Conceição et autres

INTRODUCTION: Patients with amyloid transthyretin (ATTR) amyloidosis typically experience rapid disease progression, poor treatment outcomes, irreversible loss of health-related quality of life (HRQoL), and premature mortality. Early diagnosis is vital. However, diagnostic delays and misdiagnosis are common due to under-recognition of early …

gb, de, se, pt, cn, us, ca (code pays fourni par la source)

The establishment of specific reference intervals for serum transthyretin tetramer, misfolded proteins, and protein misfolding rate and its application in evaluating transthyretin amyloidosis patients

Tingting Wang, Ming‐Shiang Wu, Ying Wang, Ying Li et autres

cn (code pays fourni par la source)

Model‐Informed Recommendation of Mavacamten Posology for Chinese Adults With Obstructive Hypertrophic Cardiomyopathy

Xiaojie Wu, Shilpa Puli, Nanye Chen, Zhuang Tian et autres

Mavacamten is a cardiac myosin inhibitor for adults with obstructive hypertrophic cardiomyopathy (HCM). Dose optimization is performed 4 weeks after starting mavacamten, guided by periodic echo measurements of Valsalva left ventricular outflow tract gradient (VLVOTg) and left ventricular ejection fraction (LVEF). Previously, …

cn, us (code pays fourni par la source)

Integrating traditional and modern medicines to treat heart failure

Zhuang Tian, Shuyang Zhang

cn (code pays fourni par la source)